Cardiovascular Disorders

Peripheral Arterial Disease (PAD)

Clinical overview and exam mastery guide covering ABI diagnosis, risk reduction therapy, claudication treatment, and revascularization decisions.

Disease Frame
Systemic atherosclerosis
Diagnostic Anchor
ABI < 0.90
Core Prevention
Antiplatelet + statin
Symptom Drug
Cilostazol

PAD Progression and Ischemic Burden

Plaque growth in limb arteries Flow drops on exertion Ischemic pain and limb risk Clinical Arc: Claudication -> Critical Limb Ischemia Non-healing ulcers, rest pain, and gangrene indicate advanced disease

PAD is both a limb disease and a high cardiovascular risk marker.

1. What Is Peripheral Arterial Disease?

Peripheral arterial disease (PAD) is a systemic atherosclerotic disease involving arteries of the limbs, most commonly lower extremities. It is strongly associated with future MI, stroke, and vascular death.

Limb ischemia Systemic risk marker Lower-extremity dominant

2. Pathophysiology

Step 1: Atherosclerotic plaque narrows peripheral arteries.
Step 2: Exertion causes oxygen supply-demand mismatch.
Step 3: Ischemic pain develops (claudication).
Step 4: Progression may lead to critical limb ischemia.

3. Clinical Presentation

A. Intermittent Claudication

  • Leg pain with walking/exertion
  • Predictably relieved by rest
  • Functional limitation over time

B. Critical Limb Ischemia

  • Rest pain
  • Non-healing ulcers
  • Gangrene and threatened limb

4. Diagnosis

ABI Formula

ABI = ankle systolic BP / brachial systolic BP

Interpretation

  • Normal: 1.0 to 1.4
  • PAD: < 0.90
  • Severe disease: < 0.40

Exam Pearl

ABI under 0.90 supports PAD diagnosis.

5. Management Goals

Reduce cardiovascular risk Improve walking symptoms Prevent limb loss

6. Foundational Therapy (All PAD Patients)

Treat PAD as a coronary-risk-equivalent state: antiplatelet therapy, high-intensity statin, blood pressure control, and smoking cessation.
Drug/Class MOA Major Side Effects Contraindications
Aspirin Irreversibly inhibits COX-1, lowering thromboxane A2 and platelet aggregation GI bleeding, dyspepsia Active bleeding
Clopidogrel P2Y12 receptor blockade, inhibiting ADP-mediated platelet aggregation Bleeding Active bleeding
High-intensity statins (atorvastatin, rosuvastatin) HMG-CoA reductase inhibition, increased LDL receptor expression Myopathy, elevated liver enzymes Active liver disease, pregnancy
In exam framing, PAD patients should receive statin therapy regardless of baseline LDL value.

7. Symptom Improvement Therapy

A. Cilostazol

  • MOA: phosphodiesterase III inhibition, increased cAMP, vasodilation, antiplatelet effect
  • Benefits: improves walking distance and claudication symptoms
  • Side effects: headache, palpitations, diarrhea
  • Contraindication: heart failure (black box warning)

B. Pentoxifylline

  • MOA: improves RBC flexibility and lowers blood viscosity
  • Clinical use: less effective than cilostazol
  • Position: not first-line for claudication symptom relief

8. Revascularization

Indications

  • Lifestyle-limiting claudication despite therapy
  • Critical limb ischemia

Approaches

  • Endovascular: angioplasty, stent
  • Surgical bypass in selected anatomy

9. Antithrombotic Intensification

In selected high-risk PAD patients, low-dose rivaroxaban plus aspirin can reduce major adverse cardiovascular and limb events.

10. Risk Factor Management

Highest Impact

  • Smoking cessation
  • Exercise therapy

Additional Control

  • Blood pressure management
  • Diabetes optimization
  • Long-term adherence monitoring
Supervised exercise programs meaningfully improve walking distance.

Management Recap Drill

PAD 1: Start antiplatelet therapy.
PAD 2: Start high-intensity statin.
PAD 3: Control BP and other risk factors.
PAD 4: Prioritize smoking cessation and exercise.
PAD 5: Add cilostazol for claudication if eligible.
PAD 6: Revascularize when severe or refractory.

Visual Algorithm Placeholder

[Insert PAD Diagnosis and Treatment Flowchart Here During UI Integration]

Guideline References (Management)

ACC/AHA Lower Extremity PAD Guideline Hub

https://www.acc.org/guidelines

Core Focus Areas

  • Antiplatelet strategy
  • Statin and risk-factor control
  • Exercise therapy and revascularization indications

11. Common Exam Traps

Cilostazol is contraindicated in heart failure.
PAD patients should receive statins even with normal LDL.
Smoking cessation has the largest impact on progression.
ABI below 0.90 supports PAD diagnosis.
Pentoxifylline is less effective than cilostazol.

12. Quick Revision Summary

Must Remember

  • PAD is systemic atherosclerosis, not an isolated limb problem
  • ABI under 0.90 is diagnostic in most exam contexts
  • All PAD patients need antiplatelet and statin backbone therapy
  • Cilostazol improves claudication but avoid in heart failure
  • Advanced disease needs revascularization planning

Practice Questions Placeholder

  • Topic: Peripheral Arterial Disease
  • Subtopics: ABI, antiplatelets, statins, cilostazol, critical limb ischemia